ClassID:

97218

C07K16/4208 - CPC Classification

Classification description:

Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig

Sub-classes:
Recent Application in this class:
#1
20260055184
2026-02-26

PROTEASE-ACTIVATED T CELL BISPECIFIC MOLECULES

#2
20260043020
2026-02-12

BINDING MEMBERS WITH ALTERED DIVERSITY SCAFFOLD DOMAINS

#3
20260042867
2026-02-12

ANTIBODY REPURPOSING

#4
20250326863
2025-10-23

METHOD AND MEANS FOR ENHANCING THERAPEUTIC ANTIBODIES

#5
20250289900
2025-09-18

ANTIBODIES CAPABLE OF BINDING TO CD27, VARIANTS THEREOF AND USES THEREOF

#6
20250289899
2025-09-18

ANTIBODIES CAPABLE OF BINDING TO CD27, VARIANTS THEREOF AND USES THEREOF

#7
20250277018
2025-09-04

Albumin-Binding Polypeptides and Uses Thereof

#8
20250243295
2025-07-31

ANTIGEN BINDING MOLECULES AND METHODS OF USE THEREOF

#9
20250163148
2025-05-22

ANTI-CAR COMPOSITIONS AND METHODS

#10
20250092128
2025-03-20

FOLR1 PROTEASE-ACTIVATABLE T CELL BISPECIFIC ANTIBODIES

#11
20240182598
2024-06-06

COMPOSITIONS AND METHODS FOR TREATING PEDIATRIC MYASTHENIA GRAVIS

#12
20230383010
2023-11-30

ANTI-IDIOTYPE ANTIBODY MOLECULES AND USES THEREOF

#13
20230212301
2023-07-06

ANTIBODIES CAPABLE OF BINDING TO CD27, VARIANTS THEREOF AND USES THEREOF

#14
20230190931
2023-06-22

Anti-TIGIT Antibodies

#15
20230181731
2023-06-15

Anti-TIGIT Antibodies

#16
20230181636
2023-06-15

ANTIBODY GENE EDITING IN B LYMPHOCYTES AND CO-EXPRESSION OF CARGO PROTEIN

#17
20230119537
2023-04-20

PROTEASE-ACTIVATED T CELL BISPECIFIC MOLECULES

#18
20230109496
2023-04-06

ANTIBODIES CAPABLE OF BINDING TO CD27, VARIANTS THEREOF AND USES THEREOF

#19
20230057263
2023-02-23

SINGLE-AND MULTI-CHAIN POLYPEPTIDES THAT BIND SPECIFICALLY TO CD3 EPSILON

#20
20230028050
2023-01-26

ANTI-IDIOTYPIC ANTIBODIES TO BCMA-TARGETED BINDING DOMAINS AND RELATED COMPOSITIONS AND METHODS

#21
20220403050
2022-12-22

Antigen binding molecules specific for an anti-CD19 scFV

#22
20220315670
2022-10-06

COMPOSITIONS AND METHODS FOR IMPROVING TUMOR PENETRATION OF TUMOR SPECIFIC ANTIBODIES

#23
20220275087
2022-09-01

PROTEASE-ACTIVATED T CELL BISPECIFIC MOLECULES

#24
20220202945
2022-06-30

METHODS FOR REDUCING TOXICITY OF A CHEMOTHERAPEUTIC DRUG

#25
20210188967
2021-06-24

Nucleic acids encoding polypeptides against IL-23

#26
20210179709
2021-06-17

ANTI-CAR COMPOSITIONS AND METHODS

#27
20200354475
2020-11-12

Antigen binding molecules specific for an anti-CD19 scFv

#28
20200331984
2020-10-22

HARNESSING PROTEIN-BASED DRUGS COMPRISING AN ANCHOR DOMAIN FOR USE ON THE OCULAR SURFACE

#29
20200317816
2020-10-08

REVERSAL BINDING AGENTS FOR ANTI-FACTOR XI/XIa ANTIBODIES AND USES THEREOF

#30
20190345230
2019-11-14

Broad-spectrum monoclonal anti-flu B antibody and uses thereof

#31
20190315867
2019-10-17

Anti-TIGIT antibodies

#32
20190256840
2019-08-22

BINDING MEMBERS WITH ALTERED DIVERSITY SCAFFOLD DOMAINS

#33
20190119383
2019-04-25

Protease-activated T cell bispecific molecules

#34
20190100591
2019-04-04

Anti-TIGIT antibodies

#35
20190099498
2019-04-04

Methods for reducing toxicity of a chemotherapeutic drug

#36
20190048089
2019-02-14

Antagonistic Antibodies Specifically Binding Human CD40 and Methods of Use

#37
20180312583
2018-11-01

Polypeptides against IL-23

#38
20180265595
2018-09-20

ANTI-CD19 scFv (FMC63) POLYPEPTIDE AND USES THEREOF

#39
20180244802
2018-08-30

ANTIBODY OR ANTIBODY FRAGMENT OF NON-IG SCAFFOLD BINDING TO A BINDING REGION OF AN ANTI-N-METHYL-D-ASPARTATE (NMDA) RECEPTOR ANTIBODY

#40
20180086846
2018-03-29

Antigen binding molecules specific for an anti-CD19 scFv

#41
20180022825
2018-01-25

Reversal binding agents for anti-factor XI/XIa antibodies and uses thereof

#42
20180016351
2018-01-18

ANTIBODIES COMPRISING SEQUENCES FROM CAMELIDAE TO HIGHLY CONSERVED TARGETS

#43
20170342164
2017-11-30

ANTI-CD19 scFv (FMC63) POLYPEPTIDE

#44
20170088624
2017-03-30

Agonistic antibodies specifically binding CD40 and methods of use

#45
20160334414
2016-11-17

Anti-MIF immunohistochemistry

#46
20160158331
2016-06-09

Compositions and methods for treatment of non-hodgkins lymphoma

#47
20160096902
2016-04-07

Anti-CD19 scFv (FMC63) polypeptide

#48
20160024502
2016-01-28

Recombinant polypeptide production

#49
20150353608
2015-12-10

Antibody-binding peptide

#50
20140227251
2014-08-14

Methods for identifying antibodies with reduced immunogenicity

#51
20140127229
2014-05-08

IP-10 antibody dosage escalation regimens

#52
20130330323
2013-12-12

Rapid generation of anti-idiotypic antibodies

#53
20130287798
2013-10-31

Uses of monoclonial antibody 8H9

#54
20120135012
2012-05-31

TRANS-MEMBRANE-ANTIBODY INDUCED INHIBITION OF APOPTOSIS

#55
20110274684
2011-11-10

CYTOTOXIC ANTIBODIES DIRECTED AGAINST ANTIBODIES INHIBITING FACTOR VIII

#56
20110236484
2011-09-29

Genus-wide chlamydial peptide vaccine antigens

#57
20110183363
2011-07-28

Assays for detecting antibodies specific to therapeutic anti-IgE antibodies and their use in anaphylaxis

#58
20100303720
2010-12-02

Variants of humanized anti-carcinoma MAb CC49

#59
20100297008
2010-11-25

Ganglioside associated recombinant antibodies and the use thereof in the treatment of tumors

#60
20100284920
2010-11-11

Uses of monoclonal antibody 8H9

#61
20100233167
2010-09-16

CHAIN REACTION CREATING OLIGOMERS FROM REPEAT UNITS OF BINDING MOLECULES

#62
20100226914
2010-09-09

Method for preparation of single chain antibodies

#63
20100063258
2010-03-11

FUSION PROTEIN CONSTRUCTS

#64
20090325815
2009-12-31

PRODUCTION OF ANTI-SELF ANTIBODIES FROM ANTIBODY SEGMENT REPERTOIRES AND DISPLAYED ON PHAGE

#65
20090325311
2009-12-31

Measurement methods

#66
20090274710
2009-11-05

TRANS-MEMBRANE-ANTIBODY INDUCED INHIBITION OF APOPTOSIS

#67
20090246795
2009-10-01

IMMUNOASSAY DEVICE AND METHOD

#68
20090220493
2009-09-03

Reagents and methods for inducing an immune response to prostate specific antigen

#69
20090130094
2009-05-21

Cytotoxic antibodies directed against antibodies inhibiting factor VIII

#70
20090081250
2009-03-26

Compositions and methods for treatment of cervical cancer

#71
20090016965
2009-01-15

INTERNAL IMAGE ANTIBODIES FOR OPTICAL IMAGING AND THERAPY

#72
20080317751
2008-12-25

Idiotype Vaccination with Bispecific and Multispecific Immunoglobulin Molecules

#73
20080127359
2008-05-29

METHOD FOR PRODUCING ANTI-IDIOTYPIC ANTIBODIES

#74
20080118939
2008-05-22

Conjugate and its use as a standard in an immunoassay

#75
20080050810
2008-02-28

Variants of humanized anti-carcinoma MAb CC49

#76
20080050359
2008-02-28

PRODUCTION OF ANTI-SELF ANTIBODIES FROM ANTIBODY SEGMENT REPERTOIRES AND DISPLAYED ON PHAGE

#77
20070232790
2007-10-04

PRODUCTION OF ANTI-SELF ANTIBODIES FROM ANTIBODY SEGMENT REPERTOIRES AND DISPLAYED ON PHAGE

#78
20070048306
2007-03-01

Method for generating anti-variable region monoclonal antibodies

#79
20060280750
2006-12-14

Toxin-related antibodies with antimicrobial and antiviral activity

#80
20060269561
2006-11-30

Compositions and methods for treatment of non-hodgkins lymphoma

#81
20060247424
2006-11-02

Anti-idiotype antibody, method of constructing the anti-idiotype antibody, and method of preparing idiotype antibody using the anti-idiotype antibody

#82
20060206947
2006-09-14

Heterodimeric protein binding compositions

#83
20060073528
2006-04-06

Measurement methods

#84
20050202018
2005-09-15

Reagents and methods for inducing an immune response to prostate specific antigen

#85
20050186202
2005-08-25

Variants of humanized anti-carcinoma monoclonal antibody CC49

#86
20050169932
2005-08-04

Uses of monoclonal antibody 8H9

#87
20050084495
2005-04-21

Altering A B cell pathology using self-derived antigens in conjunction with specific-binding cytoreductive agent

#88
20050069535
2005-03-31

Immunotherapeutic combinations for the treatment of tumours that overexpress gangliosides

#89
20050033033
2005-02-10

Trans-membrane-antibody induced inhibition of apoptosis